AstraZeneca has received a positive recommendation from NICE (the National Institute for Health and Care Excellence) for a new combination treatment for adults with advanced or unresectable liver cancer (hepatocellular carcinoma, or HCC). This is the first time a dual immunotherapy treatment has been approved for liver cancer in the UK. The treatment combines Imfinzi (durvalumab) and Imjudo (tremelimumab), known as the STRIDE regimen. The approval is based on results from the HIMALAYA phase 3 trial, which showed that this combination significantly improved survival rates compared to the standard treatment, sorafenib. Patients in England and Wales who meet the criteria will now have access to this new treatment option, offering better long-term survival in a disease where treatment choices have been limited. Liver cancer is a serious and growing problem—it makes up over 75% of primary liver cancer cases in the UK, and its rates are rising faster than any other major cancer. Unfortunately, most cases are diagnosed at an advanced stage. Tom Keith Roach from AstraZeneca said, ‘This is a big step forward for people with advanced liver cancer. For the first time, this immunotherapy combination will be available, helping more patients live five years or longer.’ Dr. David J. Pinato from Imperial College London added, ‘This new treatment fills a critical gap in liver cancer care. Having a therapy that improves long-term survival is a major advancement for patients and doctors.’ Vanessa Hebditch from the British Liver Trust also welcomed the decision, saying, ‘This new treatment option is a real difference-maker for patients and their families.’